<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Fecal immunochemical testing (FIT) is increasingly used for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) screening </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to estimate its diagnostic accuracy in invitational population screening measured against colonoscopy </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Participants (50-75 years) in an invitational primary colonoscopy screening program were asked to complete one sample FIT before colonoscopy </plain></SENT>
<SENT sid="3" pm="."><plain>We estimated FIT sensitivity, specificity, and predictive values in detecting <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> (<z:mp ids='MP_0002038'>carcinomas</z:mp> and advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath>) for cutoff levels of 50 (FIT50), 75 (FIT75), and 100 (FIT100) ng <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (Hb)/ml, corresponding with, respectively, 10, 15 and 20 μg Hb/g feces </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: A total of 1,256 participants underwent a FIT and screening colonoscopy </plain></SENT>
<SENT sid="5" pm="."><plain>Advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> was detected by colonoscopy in 119 (9%), 8 (0.6%) of them had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>At FIT50, 121 (10%) had a positive test result; 45 (37%) had advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> and 7 (6%) had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>A total of 74 of 1,135 FIT50 negatives (7%) had advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> including 1 (0.1%) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>FIT50 had a sensitivity of 38% (95% confidence interval (CI): 29-47) for advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> and 88% (95% CI: 37-99) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> at a specificity of 93% (95% CI: 92-95) and 91% (95% CI: 89-92), respectively </plain></SENT>
<SENT sid="9" pm="."><plain>The positive and negative predictive values for FIT50 were 6% (95% CI: 3-12) and almost 100% (95% CI: 99-100) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, and 37% (95% CI: 29-46) and 93% (95% CI: 92-95) for advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>The sensitivity and specificity of FIT75 for advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> were 33% (95% CI: 25-42) and 96% (95% CI: 94-97) </plain></SENT>
<SENT sid="11" pm="."><plain>At FIT100, 71 screenees (6%) had a positive test result </plain></SENT>
<SENT sid="12" pm="."><plain>The sensitivity and specificity of FIT100 were for advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> 31% (95% CI: 23-40) and 97% (95% CI: 96-98), and for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> 75% (95% CI: 36-96) and 95% (95% CI: 93-96) </plain></SENT>
<SENT sid="13" pm="."><plain>The area under curve for detecting advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> was 0.70 (95% CI: 0.64-0.76) </plain></SENT>
<SENT sid="14" pm="."><plain>FIT had a similar sensitivity for proximal and distal advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> at cutoffs of 50 (38% vs. 37%; P=0.99), 75 (33% vs. 31%; P=0.85) and 100 (33% vs. 29%; P=0.68) ng Hb/ml </plain></SENT>
<SENT sid="15" pm="."><plain>DISCUSSION: Nine out of ten screening participants with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and four out of ten with advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> will be detected using one single FIT at low cutoff </plain></SENT>
<SENT sid="16" pm="."><plain>Sensitivity in detecting proximal and distal advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> is comparable </plain></SENT>
</text></document>